(Reuters) – The European Union’s medicines regulator did not mention Eisai and Biogen’s Alzheimer’s drug in its notes and recommendations on Friday.
The European Medicines Agency had said it would hold a oral hearing to discuss the drug, lecanemab, this week.
The drug, sold as Leqembi in the United States has been under review in Europe since January 2023. It gained traditional approval in the United States last year and is also approved in other countries, including China and Japan.
The infusion given twice a month removes sticky clumps of a protein called amyloid beta, believed to be a hallmark of Alzheimer’s, from the brain.
(Reporting by Manas Mishra and Puyaan Singh in Bengaluru; Editing by Alan Barona, Josephine Mason and Shinjini Ganguli)
